DAM
BTAI icon

DLD Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

DLD Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,088
Closed -$956K – 86
2019
Q4 		$956K Buy
+4,088
New +$411K 0.05% 77

Other funds holding BTAI

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DLD Asset Management's BTAI Position: Q1 2020 in Review

DLD Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2020, closing a stake of 4,088 shares — an estimated $956K sold.

DLD Asset Management first reported a position in BTAI in Q4 2019 and held it in 1 quarter. The position peaked at $956K in Q4 2019. 70 funds tracked by Wall St. Rank hold BTAI as of Q1 2020.

  • DLD Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2020 after selling out during the quarter.
  • DLD Asset Management sold 4,088 BioXcel Therapeutics shares in Q1 2020, an estimated $956K.
  • DLD Asset Management first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 1 quarter.
  • DLD Asset Management's BioXcel Therapeutics position peaked at $956K in Q4 2019.
  • 70 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2020.

Based on DLD Asset Management's 13F filing for Q1 2020, filed 14 May 2020.